GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week ...

GLP-1 medications were initially developed and prescribed to help manage blood sugar in people with Type 2 diabetes ...

Research found that the weight-loss medications may reduce the spread of several obesity-related cancers, including lung, ...

Glucagon-like peptide-1 receptor agonists vs alternative therapies are not associated with increased risk for suicide and may lower risk.

By HealthDay Staff HealthDay ReporterWEDNESDAY, May 27, 2026 (HealthDay News) — A new study suggests GLP-1 medications may ...

GLP-1 medications used for diabetes and weight loss may do more than help control blood sugar and appetite. A new study ...

GLP-1 drugs, such as Ozempic and Wegovy, may slow down the spread of obesity-related cancers, according to researchers ...

GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several ...

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. This study included 910 initiators of GLP-1RAs and 1004 initiators ...